<DOC>
	<DOC>NCT02097095</DOC>
	<brief_summary>This is an independent optional sub-study parallel to TB-018 (NCT01755598) in which biological samples will be collected for future investigations on biological correlates, markers or prognostic factors for TB disease. Subjects who consent to enroll in TB-018, "A phase IIb, double-blind, randomised, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate tuberculosis (TB) vaccine GSK 692342 (M72/AS01E) against TB disease, in healthy adults aged 18-50 years, living in a TB endemic region", (see NCT 01755598) will be asked to participate in this sub-study. Subjects enrolled in TB-018 who also consent to C-041-972 will be followed according to the TB-018 protocol but will have additional blood samples collected for the sub-study.</brief_summary>
	<brief_title>Substudy of Protocol TB-018 (NCT01755598): Collection and Storage of Biological Samples for Evaluation of Correlates of TB (C-041-972)</brief_title>
	<detailed_description>Additional information in the protocol</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>To be eligible for this substudy, subjects must be enrolled in TB018 and provide separate written informed consent for C041972. See NCT 01755598 for inclusion criteria into TB018. Exclusion criteria: To be eligible for this substudy, subjects must be enrolled in TB018 and provide separate written informed consent for C041972. See NCT 01755598 for exclusion criteria into TB018.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Correlates of risk</keyword>
	<keyword>TB</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>Sub-study</keyword>
	<keyword>TB-018</keyword>
</DOC>